Integra Lifesciences Holdings (IART) Net Cash Flow (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Net Cash Flow data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 127.56% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at -$14.3 million (up 95.98% YoY), and the FY2025 full-year result was -$29.3 million, down 24.53% from the prior year.
• Net Cash Flow improved to $3.3 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $320.5 million in Q1 2024 to a low of -$375.5 million in Q2 2024.
• A 5-year average of -$16.5 million and a median of -$5.4 million in 2023 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 832.74% in 2024, while the deepest fall reached 18527.13% in 2024.
• Tracing IART's Net Cash Flow over 5 years: stood at -$67.2 million in 2022, then jumped by 92.01% to -$5.4 million in 2023, then jumped by 832.74% to $39.3 million in 2024, then slumped by 96.82% to $1.3 million in 2025, then soared by 159.95% to $3.3 million in 2026.
• Business Quant data shows IART's Net Cash Flow at $3.3 million in Q1 2026, $1.3 million in Q4 2025, and $15.1 million in Q3 2025.